jnj-89862175
jnj-89862175: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: GH Research PLC (GHRS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| GH Research PLC (GHRS) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors
Frequently asked questions
Who is developing jnj-89862175?
jnj-89862175 is being developed by GH Research PLC.
How many clinical trials involve jnj-89862175?
BioSniper tracks 1 clinical trial involving jnj-89862175.
Analyze GH Research PLC & jnj-89862175 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company